Michael R Grever

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
    Michael R Grever
    Eastern Cooperative Oncology Group, Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 25:799-804. 2007
  2. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
  3. pmc How I treat hairy cell leukemia
    Michael R Grever
    Department of Internal Medicine, Ohio State University, Columbus, OH, USA
    Blood 115:21-8. 2010
  4. doi request reprint Long-term follow-up studies in hairy cell leukemia
    Michael R Grever
    Department of Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 50:23-6. 2009
  5. doi request reprint Modern strategies for hairy cell leukemia
    Michael R Grever
    The Ohio State University Medical Center, Columbus, OH, USA
    J Clin Oncol 29:583-90. 2011
  6. doi request reprint Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas
    Michael R Grever
    Department of Pharmacology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 52:25-8. 2011
  7. ncbi request reprint Pentostatin: impact on outcome in hairy cell leukemia
    Michael R Grever
    Department of Internal Medicine, The Ohio State University, 1654 Upham Drive, Room 215 Means Hall, Columbus, 43210, USA
    Hematol Oncol Clin North Am 20:1099-108. 2006
  8. ncbi request reprint Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia
    Michael R Grever
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Best Pract Res Clin Haematol 20:545-56. 2007
  9. pmc Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
    Mitch A Phelps
    Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:2637-45. 2009
  10. pmc The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 113:4656-66. 2009

Collaborators

Detail Information

Publications94

  1. ncbi request reprint Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997
    Michael R Grever
    Eastern Cooperative Oncology Group, Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    J Clin Oncol 25:799-804. 2007
    ..1), and p53 mutations have been reported to predict the clinical course and overall survival of patients with chronic lymphocytic leukemia (CLL). In addition, ZAP-70 and Bcl-2 family proteins have been explored as predictors of outcome...
  2. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
    ..We examined here the preclinical activity of silvestrol in FLT3-ITD and FLT3 wild-type (wt) AML...
  3. pmc How I treat hairy cell leukemia
    Michael R Grever
    Department of Internal Medicine, Ohio State University, Columbus, OH, USA
    Blood 115:21-8. 2010
    ..Continued clinical research is essential to optimize therapy for this disease...
  4. doi request reprint Long-term follow-up studies in hairy cell leukemia
    Michael R Grever
    Department of Medicine, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 50:23-6. 2009
    ..Patients with this disease now can live a near normal life expectancy, but the disease has not yet been cured. Clinical trials must continue to address the remaining unanswered questions...
  5. doi request reprint Modern strategies for hairy cell leukemia
    Michael R Grever
    The Ohio State University Medical Center, Columbus, OH, USA
    J Clin Oncol 29:583-90. 2011
    ..Consideration of the median age of patients at diagnosis combined with a substantial relapse rate mandates continued pursuit of improved therapy. The ultimate goal will be to achieve cure rather than simple control of the disease...
  6. doi request reprint Hairy cell leukemia: a successful model for experimental therapeutics--pentostatin and new ideas
    Michael R Grever
    Department of Pharmacology, The Ohio State University, Columbus, OH, USA
    Leuk Lymphoma 52:25-8. 2011
    ..g. importance of minimal residual disease) and will require international collaboration to fully address these unanswered questions. The Hairy Cell Leukemia Consortium was established to address these unanswered questions...
  7. ncbi request reprint Pentostatin: impact on outcome in hairy cell leukemia
    Michael R Grever
    Department of Internal Medicine, The Ohio State University, 1654 Upham Drive, Room 215 Means Hall, Columbus, 43210, USA
    Hematol Oncol Clin North Am 20:1099-108. 2006
    ..Future studies should be directed to optimizing the therapy for minimal residual disease as well as clearer definition of supportive care...
  8. ncbi request reprint Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia
    Michael R Grever
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Best Pract Res Clin Haematol 20:545-56. 2007
    ..1) is a major focus of several investigators. Selection of therapy based on high-risk genomic features represents an appropriate treatment approach supported by currently available published data...
  9. pmc Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
    Mitch A Phelps
    Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:2637-45. 2009
    ..These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, genetically high-risk CLL. Furthermore, PK describes some, but not all, variability in response and toxicity...
  10. pmc The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 113:4656-66. 2009
    ..These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias...
  11. pmc Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 27:6012-8. 2009
    ..Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated...
  12. pmc Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
    ..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
  13. pmc Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:418-23. 2010
    ..We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR...
  14. pmc Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
    ....
  15. ncbi request reprint Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:437-43. 2006
    ..1), and p53 mutations. To date, the impact of these same prognostic factors have not been examined relative to treatment outcome with chemoimmunotherapy...
  16. pmc Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia
    Alison R Walker
    Division of Hematology, Department of Internal Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Leuk Lymphoma 54:1996-2002. 2013
    ..Pharmacokinetic data provide insight for studies of related agents in AML. Next-generation HSP90 inhibitors are appealing for further development in this area. ..
  17. doi request reprint Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia
    Deborah M Stephens
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, United States
    Leuk Res 37:1195-9. 2013
    ..CAR was tolerable and active in high-risk CLL patients without TLS toxicity. With continued monitoring of toxicities, a phase Ib/II study of this combination as frontline therapy is warranted. ..
  18. ncbi request reprint Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
    Syed Rehan A Hussain
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 13:2144-50. 2007
    ..Mcl-1 has also been reported to mediate resistance to rituximab in CLL. We therefore investigated whether direct reduction of Mcl-1 was sufficient to induce apoptosis and increase sensitivity to rituximab...
  19. pmc Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia
    Neil E Kay
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 116:2180-7. 2010
    ..The combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) achieved an overall response (OR) rate >90%, with >40% complete responses (CRs) in patients with untreated chronic lymphocytic leukemia (CLL)...
  20. doi request reprint Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma
    Jeffrey A Jones
    Division of Hematology, The Ohio State University, Columbus, Ohio
    Am J Hematol 89:19-24. 2014
    ..The single-agent activity of this first-generation CDKI suggests that other agents in this class merit further study in lymphoid malignancies, both alone and in combination...
  21. pmc A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol
    Jia Ji
    The Comprehensive Cancer Center, College of Pharmacy, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 19:1269-80. 2013
    ..The purpose of this study was to investigate the relationships between pretreatment risk factors, drug pharmacokinetics, and TLS...
  22. pmc Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach
    Deborah M Stephens
    Division of Hematology, Department of Internal Medicine and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Haematologica 97:423-7. 2012
    ..Development of treatment approaches including flavopiridol should be considered for these older patients...
  23. pmc A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
    Invest New Drugs 30:629-38. 2012
    ....
  24. pmc Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
    Farrukh T Awan
    The Ohio State University, Columbus, USA
    Blood 113:535-7. 2009
    ..Because the trials described were conducted before the requirement to register them was implemented, they are not registered in a clinical trial database.)...
  25. pmc A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels
    Ping Chen
    College of Pharmacy, The Ohio State University, 500 W 12th Avenue, Columbus, OH 43210, USA
    Pharm Res 26:1504-15. 2009
    ..To simultaneously quantify intracellular nucleoside triphosphate (NTP) and deoxynucleoside triphosphate (dNTP) pools and to assess their changes produced by interfering with ribonucleotide reductase (RNR) expression in leukemia cells...
  26. ncbi request reprint Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia
    Amy J Johnson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Br J Haematol 139:837-44. 2007
    ..Furthermore, our data indicates that AKT and Hsp70 protein levels are relevant pharmacodynamic endpoints to monitor the in vivo effect of 17-AAG therapy...
  27. pmc Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease
    Ming J Poi
    Department of Pharmacy, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH, USA
    Clin Pharmacokinet 52:705-12. 2013
    ..This phase II study (NCT00201786) was conducted to assess pentostatin efficacy and infectious complications seen from our previous phase I study in steroid-refractory acute GVHD (aGVHD)...
  28. pmc ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
    Emilia Mahoney
    Division of Hematology, Department of Internal Medicine, College of Pharmacy, The Ohio State University OSU, Columbus, OH 43210, USA
    Blood 120:1262-73. 2012
    ....
  29. pmc The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo
    David M Lucas
    Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    PLoS ONE 5:e10941. 2010
    ..We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies...
  30. pmc Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia
    Tait D Shanafelt
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 146:660-4. 2009
    ..The pretreatment VEGF:TSP ratio also correlated with overall survival (P = 0.008). A pro-angiogenic profile appears associated with diminished response and inferior survival in CLL patients receiving CIT...
  31. pmc Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma
    Qing Liu
    Division of Pharmaceutics, College of Pharmacy, Comprehensive Cancer Center, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA
    Ther Drug Monit 30:620-7. 2008
    ..This sensitivity will enable late terminal phase concentration measurements and accurate pharmacokinetic parameter estimation in a planned clinical trial with lenalidomide and flavopiridol in patients with chronic lymphocytic leukemia...
  32. pmc Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein
    Craig C Hofmeister
    The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 29:3427-34. 2011
    ..The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM...
  33. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  34. pmc Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 150:189-95. 2010
    ..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL...
  35. doi request reprint A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
    Thomas S Lin
    Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:1958-63. 2009
    ..Given the toxicity and lack of efficacy in this and other trials in lymphoma and solid tumors, further development of apolizumab was discontinued...
  36. ncbi request reprint Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia
    Tait D Shanafelt
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 109:2291-8. 2007
    ..Although chemoimmunotherapy (CIT) has dramatically improved response rates in patients with CLL, some CIT regimens are not well tolerated by many patients >or=70 years of age...
  37. pmc A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
    Tanios S Bekaii-Saab
    Division of Hematology and Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Mol Cancer Ther 8:2983-91. 2009
    ..IL-12 in combination with trastuzumab and paclitaxel therefore exhibits an acceptable toxicity profile and has activity in patients with HER2-overexpressing cancers...
  38. pmc Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, B310 Starling Loving Hall, Columbus, OH 43210, USA
    Blood 119:6025-31. 2012
    ..This study demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML and identifies FLT3 as a novel pharmacodynamic end point for future trials...
  39. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  40. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  41. pmc Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
    Syed Rehan A Hussain
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:3190-9. 2008
    ..These observations suggest that in CLL and 697 cells, flavopiridol mediates its cytotoxic effects via induction of the mitochondrial permeability transition and changes in intracellular calcium...
  42. pmc Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
    John C Byrd
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 109:399-404. 2007
    ..Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases...
  43. ncbi request reprint Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder
    Sameek Roychowdhury
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, USA
    J Natl Cancer Inst 96:1447-57. 2004
    ..We evaluated the effect of depsipeptide, a histone deacetylase inhibitor, on EBV-positive lymphoblastoid cell lines (LCLs) and Burkitt lymphoma cell lines in a mouse model and explored its mechanism of action in vitro...
  44. pmc Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    William Blum
    Division of Hematology and Oncology, Department of Medicine, and Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:7473-8. 2010
    ..Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment...
  45. pmc Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol
    Lapo Alinari
    Department of Internal Medicine, College of Medicine, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 18:4600-11. 2012
    ..We hypothesized that this dual activity of silvestrol would make it especially effective in malignancies driven by aberrant cyclin D1 expression...
  46. pmc A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors
    Bhuvaneswari Ramaswamy
    The Ohio State University, B401, Starling Loving Hall, 320 W 10th av, Columbus, OH 43210, USA
    Cancer Chemother Pharmacol 66:151-8. 2010
    ..A phase I study to determine the maximum tolerated dose (MTD) of bortezomib (B) when combined with weekly paclitaxel in patients with advanced solid tumors...
  47. doi request reprint Flavopiridol in chronic lymphocytic leukemia: a concise review
    Beth A Christian
    Division of Hematology Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Lymphoma Myeloma 9:S179-85. 2009
    ..Several other investigational CDKi in preclinical and early clinical development are briefly discussed in this review...
  48. pmc Dose escalation of lenalidomide in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 28:4919-25. 2010
    ..Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia...
  49. pmc Development and validation of a rapid and sensitive high-performance liquid chromatography-mass spectroscopy assay for determination of 17-(allylamino)-17-demethoxygeldanamycin and 17-(amino)-17-demethoxygeldanamycin in human plasma
    Jeffrey S Johnston
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 871:15-21. 2008
    ..It is the first analytical method reported to date for the quantitation of both 17AAG and its metabolite 17AG and can reliably quantitate concentrations of both compounds as low as 0.5 ng/mL...
  50. pmc Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
    Rebecca B Klisovic
    Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 14:3889-95. 2008
    ....
  51. pmc A novel liposomal formulation of flavopiridol
    Xiaojuan Yang
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Int J Pharm 365:170-4. 2009
    ..Further preclinical studies are warranted to define the toxicity and therapeutic efficacy of this novel formulation...
  52. pmc A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
    Amir Mortazavi
    Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University and the Comprehensive Cancer Center, A454 Starling Loving Hall, 320 West 10th Ave, Columbus, OH, 43210, USA
    Invest New Drugs 31:685-95. 2013
    ..We conducted a phase I trial to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of prolonged triapine infusion followed by FDR-G...
  53. ncbi request reprint Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia
    Aparna Raval
    Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, The Comprehensive Cancer Center at The Ohio State University, Columbus, OH 43214, USA
    Cell 129:879-90. 2007
    ..Thus, reduced expression of DAPK1 can result from germline predisposition, as well as epigenetic or somatic events causing or contributing to the CLL phenotype...
  54. pmc In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia
    Hongyan Wang
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    AAPS J 15:242-9. 2013
    ..Higher levels are seemingly associated with clinical response. Monitoring the DAC-TP intracellular level may serve as a novel pharmacological endpoint for designing more effective DAC-based regimens...
  55. pmc Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia
    Samantha M Jaglowski
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    Br J Haematol 159:82-7. 2012
    ..In patients with high-risk interphase cytogenetics, CK remained predictive of worse OS (P = 0·02) and EFS (P = 0·009). These findings support further evaluation of metaphase karyotype in transplant risk assessment...
  56. pmc Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition
    Wenjun Ni
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio, United States of America
    PLoS ONE 5:e13792. 2010
    ..This study aimed to evaluate pharmacogenetic factors associated with inter-individual variability in pharmacokinetics and outcomes associated with flavopiridol therapy...
  57. ncbi request reprint A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
    John C Byrd
    Department of Internal Medicine, Division of Hematology Oncology, Starling Loving Hall, Rm 302, The Ohio State University, Columbus, OH 43210, USA
    Blood 105:959-67. 2005
    ..Future studies with depsipeptide should examine alternative administration schedules...
  58. ncbi request reprint Flavopiridol in the treatment of chronic lymphocytic leukemia
    Beth A Christian
    Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
    Curr Opin Oncol 19:573-8. 2007
    ..This review focuses on a novel dosing regimen that has achieved significant clinical activity in relapsed, poor-risk chronic lymphocytic leukemia...
  59. pmc Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry
    U V R Vijaya Saradhi
    College of Pharmacy, The Ohio State University, Columbus, 43210, USA
    AAPS J 13:347-56. 2011
    ..Together, these data suggest an overall favorable pharmacokinetic profile of silvestrol in mice and provide crucial information for its continued development toward potential clinical testing...
  60. ncbi request reprint Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
    Naeem A Ali
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer 110:96-102. 2007
    ..The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population...
  61. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805
    John C Byrd
    Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:4176-81. 2005
    ..We sought to determine if flavopiridol has activity in previously treated CLL using two schedules of administration...
  62. pmc Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
    Amy J Johnson
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:1334-8. 2006
    ....
  63. pmc Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia
    Xiaodan Su
    Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Proteomics 9:1197-206. 2009
    ..Protein identities were determined using high mass accuracy MS and shotgun proteomics...
  64. ncbi request reprint Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteria
    Kristie A Blum
    The Ohio State University, Division of Hematology Oncology, Starling Loving Hall, Room B324, Columbus, OH 43210, USA
    J Clin Oncol 25:5624-9. 2007
    ..The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria...
  65. pmc Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule
    Mitch A Phelps
    Comprehensive Cancer Center, College of Pharmacy, The Ohio State University, Columbus, OH, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 868:110-5. 2008
    ....
  66. ncbi request reprint New drugs in acute myeloid leukemia
    Michael R Grever
    Ohio State University, Columbus, OH 43210, USA
    Clin Adv Hematol Oncol 1:456-9. 2003
  67. ncbi request reprint Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
    Gerard Lozanski
    Department of Pathology, Ohio State University, Columbus, OH 43210, USA
    Blood 103:3278-81. 2004
    ..The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions...
  68. pmc Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells
    Sneha V Gupta
    College of Pharmacy, The Ohio State University, Columbus, USA
    AAPS J 13:357-64. 2011
    ..Together, these data indicate that silvestrol is a substrate of Pgp, a potential obstacle that must be considered in the development of silvestrol for oral delivery or targeting to tumors protected by Pgp overexpression...
  69. ncbi request reprint Antibody therapy for chronic lymphocytic leukemia: a promising new modality
    Thomas S Lin
    Division of Hematology and Oncology, Starling Loving Hall, Room 302, The Arthur James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Hematol Oncol Clin North Am 18:895-913, ix-x. 2004
    ..Future efforts in developing combination strategies with rituximab, alemtuzumab, and potentially other new antibodies offer great promise for the future treatment of CLL...
  70. ncbi request reprint Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein
    Jennifer L Aron
    Department of Internal Medicine, The Division of Hematology Oncology, The Ohio State University, Columbus, USA
    Blood 102:652-8. 2003
    ..These data suggest use of histone H3 and H4 acetylation, inhibition of histone deacetylase, and down-regulation of FLIP as pharmacodynamic end points for further evaluation of this drug in patients...
  71. pmc Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)
    Eric H Kraut
    Arthur G James Cancer Hospital and Richard J Solove Research Institute, College of Medicine and The Ohio State University Medical Center, Columbus, OH, USA
    Cancer Chemother Pharmacol 67:579-86. 2011
    ..This phase I study determined the maximal-tolerated dose, dose-limiting toxicities, pharmacokinetics, and recommended dose of erlotinib with docetaxel...
  72. doi request reprint Salvage therapy for relapsed chronic lymphocytic leukemia
    Leslie A Andritsos
    The Ohio State University, Columbus, OH 43210, USA
    Expert Rev Hematol 4:199-212. 2011
    ....
  73. ncbi request reprint TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia
    Aparna Raval
    Division of Human Cancer Genetics, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 23:3877-85. 2005
    ..Herein we report selective epigenetic silencing of the transcription factor TWIST2 (DERMO1) in Ig V(H) mutated CLL and describe a semiquantitative assay to study promoter methylation of this gene in primary tumor cells...
  74. ncbi request reprint Pentostatin in the treatment of hairy-cell leukemia
    Michael R Grever
    Department of Internal Medicine, Ohio State University, Room 215, Means Hall 1654, Upham Drive, Columbus, OH 43210, USA
    Best Pract Res Clin Haematol 16:91-9. 2003
    ..New studies should explore the combination of pentostatin and rituxan in treating the typical form of hairy-cell leukemia, and the incorporation of new agents for those with the rare variant form of this disease...
  75. pmc Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma
    Sharmistha Pal
    Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, OH 43210, USA
    EMBO J 26:3558-69. 2007
    ..Thus, our studies indicate that aberrant expression of PRMT5 leads to altered epigenetic modification of chromatin, which in turn impacts transcriptional performance of anti-cancer genes and growth of transformed lymphoid cells...
  76. doi request reprint A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors
    Tanios S Bekaii-Saab
    Division of Hematology and Oncology, The Ohio State University, A434B Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Clin Cancer Res 14:3434-40. 2008
    ....
  77. ncbi request reprint Treatment of relapsed chronic lymphocytic leukemia: old and new therapies
    John C Byrd
    Division of Hematology and Oncology, The Ohio State University, The Arthur James Comprehensive Cancer Center, Columbus, OH 43210, USA
    Semin Oncol 33:210-9. 2006
    ..We discuss selection of therapy for the relapsed patient using risk stratification and the role of clinical research in continuing to pursue therapeutic advances against CLL...
  78. ncbi request reprint Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Guido Marcucci
    Division of Hematology Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA
    Blood 101:425-32. 2003
    ..The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML (ie, age at least 60 years)...
  79. ncbi request reprint Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study
    Charles F Eisenbeis
    Division of Hematology Oncology, Comprehensive Cancer Center, and Center for Biostatistics, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 10:6101-10. 2004
    ..We also conducted a phase I trial of IL-2 and rituximab in relapsed B-NHL to study whether expansion of natural killer (NK) cells and enhanced cellular cytotoxicity could be safely accomplished in vivo...
  80. ncbi request reprint Quantification of valproic acid and its metabolite 2-propyl-4-pentenoic acid in human plasma using HPLC-MS/MS
    Hao Cheng
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, OH 43210, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 850:206-12. 2007
    ..This method has been applied to the analysis of plasma samples obtained from patients treated with this drug...
  81. pmc Potential of plant-derived natural products in the treatment of leukemia and lymphoma
    David M Lucas
    Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 410 W 12th Avenue, Columbus, OH 43210, USA
    Curr Drug Targets 11:812-22. 2010
    ....
  82. ncbi request reprint KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis
    John C Byrd
    Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 101:4547-50. 2003
    ..These data demonstrate KRN5500 has significant in vitro activity against human CLL cells, thus providing support for introduction of this agent into clinical trials for patients with CLL...
  83. pmc Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors
    Pravin T P Kaumaya
    Department of Obstetrics and Gynecology, Division of Reproductive Biology and Vaccine Research, Ohio StateUniversity, Columbus, OH 43210, USA
    J Clin Oncol 27:5270-7. 2009
    ..5%) and were associated with no serious adverse events, autoimmune disease, or cardiotoxicity. There was preliminary evidence of clinical activity in several patients...
  84. doi request reprint Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents
    Janet E Dancey
    Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 16:1745-55. 2010
    ..The Task Force provides these guidelines in the hopes that improvements in biomarker studies will enhance the efficiency of investigational drug development...
  85. ncbi request reprint Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation
    Steven Z Pavletic
    Department of Internal Medicine, Section of Oncology Hematology, University of Nebraska Medical Center, Omaha, NE, USA
    Transplantation 76:877-81. 2003
    ..5% donor CD3 lymphocytes. PT demonstrated lymphodepleting effects and promising safety, supporting alloNST as early as 7 days after initiation of PT...
  86. ncbi request reprint A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma
    Carl R Willis
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Ann Hematol 85:301-7. 2006
    ..5 months for nonresponders. The combination of pentostatin, chlorambucil, and theophylline is the active regimen in patients with FL and B-cell CLL...
  87. ncbi request reprint Changing the way we think about chronic lymphocytic leukemia
    Thomas S Lin
    J Clin Oncol 23:4009-12. 2005
  88. ncbi request reprint Pentostatin in steroid-refractory acute graft-versus-host disease
    Javier Bolaños-Meade
    Division of Hematologic Malignancies, Department of Oncology, Johns Hopkins Univeristy, Baltimore, MD 21231, USA
    J Clin Oncol 23:2661-8. 2005
    ..In steroid-refractory aGVHD, mortality is very high. Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and may be useful in the treatment of this condition...
  89. ncbi request reprint Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity
    Ian W Flinn
    Department of Oncology, John Hopkins University, Baltimore, MD, USA
    Leuk Res 29:1253-7. 2005
    ..Based upon this pre-clinical data, a phase I/II study of 24h flavopiridol was performed...
  90. ncbi request reprint Community-based phase II trial of PCR for CLL/SLL patients
    Neil E Kay
    Cancer Biother Radiopharm 22:713-4; author reply 715-7. 2007
  91. ncbi request reprint Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
    Steven D Gore
    The Johns Hopkins Oncology Center, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 8:963-70. 2002
    ..Two patients on the 21/28 schedule developed hematological improvement. Prolonged infusions of PB are well tolerated making this an attractive platform for the clinical investigation of HDAC inhibition...
  92. ncbi request reprint Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
    Ian W Flinn
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 25:793-8. 2007
    ..E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL...
  93. pmc Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
    Laura Z Rassenti
    The Chronic Lymphocytic Leukemia Research Consortium, La Jolla, CA, USA
    Blood 112:1923-30. 2008
    ....
  94. ncbi request reprint Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia
    Yvette L Kasamon
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 11:8413-7. 2005
    ....